Premal Patel is a physician-scientist with 15 years of experience in medical oncology drug development, thoughtfully combining clinical strategy with adept biomarker approaches. Most recently, Premal was the SVP, Head of Early Clinical Drug Development at Juno therapeutics where he led CART efforts in multiple myeloma and all solid tumor CART & TCR efforts. Prior to this, he was VP, Head Early Clinical Development and Translational Research at Pfizer, where he led the allogenic CART effort, along with ~15 immuno-oncology assets.

He spent over 7 years at Genentech, Research and Early Development leading clinical development for several agents, including: aPD-L1+Avastin in renal cell carcinoma and AKT inhibitor (ipatasertib) across indications from inception to successful proof-of-concept at end of Phase 2.

Premal received BS Pharmacy from Rutgers University; MD and PhD degrees at University of Washington. He completed internal medicine at University of Washington and adult medical oncology at Memorial Sloan Kettering Cancer Center, where he researched targeted therapies for renal cell carcinoma.